Scientists from the Institute of Cancer Research (ICR), London, UK, have developed an algorithm that can predict whether ...

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3, ...

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences ...

In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at significantly higher risk for potential harms, according to two systematic reviews.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

Johnson & Johnson JNJ announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine ...

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...

Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that ...